Skip to main content

Foundation Medicine, Novartis Partner on Cancer Diagnostic

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pharmacogenomic test development firm Foundation Medicine today announced a collaboration with Novartis to develop, enhance, and optimize Foundation's cancer genome panel test.

The deal is Foundation's first with a drug firm, and if the pilot phase is successful the two companies will evaluate opportunities to commercialize the test.

"By delivering a clinical-grade analysis of molecular information, Foundation's dedicated clinical research team will help our partners more rapidly translate novel findings into therapeutically applicable results," Alexis Borisy, CEO of Cambridge, Mass.-based Foundation, said in a statement. "This collaboration is an important step forward for Foundation and could provide us with the basis for building successful cancer genome analysis platforms for future collaborations and partners."

Financial and other terms of the deal were not disclosed.

Privately-held Foundation raised $25 million in a Series A round of financing last April.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.